EFFICACY AND SAFETY OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO DEMONSTRATED INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITION: WEEK 24 RESULTS OF A PHASE 3B, RANDOMIZED, CONTROLLED STUDY

Coates LC, Gossec L, Theander E, Bergmans P, Neuhold M, Karyekar C, Shawi M, Noel W, Schett G, Mcinnes I (2021)

Publication Type: Conference contribution

Publication year: 2021

Journal

Annals of the Rheumatic Diseases BMJ Publishing Group

Publisher: BMJ PUBLISHING GROUP

City/Town: LONDON

Pages Range: 140-141

Conference Proceedings Title: ANNALS OF THE RHEUMATIC DISEASES

DOI: 10.1136/annrheumdis-2021-eular.42

Authors with CRIS profile

Georg Schett Lehrstuhl für Innere Medizin III

Involved external institutions

University of Oxford GB United Kingdom (GB) University of Paris 4 - Paris-Sorbonne / Université paris IV Paris-Sorbonne FR France (FR) Janssen Global Services, LLC US United States (USA) (US) Janssen-Cilag GmbH DE Germany (DE) University of Glasgow GB United Kingdom (GB)

How to cite

APA:

Coates, L.C., Gossec, L., Theander, E., Bergmans, P., Neuhold, M., Karyekar, C.,... Mcinnes, I. (2021). EFFICACY AND SAFETY OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO DEMONSTRATED INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITION: WEEK 24 RESULTS OF A PHASE 3B, RANDOMIZED, CONTROLLED STUDY. In ANNALS OF THE RHEUMATIC DISEASES (pp. 140-141). LONDON: BMJ PUBLISHING GROUP.

MLA:

Coates, L. C., et al. "EFFICACY AND SAFETY OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO DEMONSTRATED INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITION: WEEK 24 RESULTS OF A PHASE 3B, RANDOMIZED, CONTROLLED STUDY." Proceedings of the ANNALS OF THE RHEUMATIC DISEASES LONDON: BMJ PUBLISHING GROUP, 2021. 140-141.

BibTeX: Download